Felix Lorenz
Co-founder, Chief Executive & Scientific Officer Captain T Cell
Felix Lorenz, PhD, is CEO and CSO of Captain T Cell, a biotech pioneering next-generation TCR-T cell therapies for solid tumors and CAR-T cell therapies for hematological tumors. He leads the company’s scientific and strategic direction, translating cutting-edge immunology into transformative cancer treatments. Under his leadership, Captain T Cell has secured significant venture backing and advanced platforms to increase efficacy of TCR- and CAR-T cells. Felix holds a PhD in Molecular Immunology from Humboldt University Berlin and has authored patents in T cell engineering. His work bridges scientific innovation, clinical potential, and entrepreneurial impact in cell-based cancer immunotherapy.
Seminars
- SWITCH significantly increases potency of TCR- and CAR-T cells against tumors
- SWITCH receptor targeting TGF-beta, a key defense line of the hostile tumor microenvironment
- SWITCH may be suitable for efficacyenhancing autologous, allogeneic and in vivo T-cell therapies of solid and hematological tumors
